Last 12 months
Inside the activity.
1 purchase rows · 3 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 1 | 0 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 13, 2023 Filed Nov 15, 2023 17:26 UTC |
Brunn CarstenDirector · President and CEO
|
Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 1,000,000 | Not disclosed Strike: $6.03 | Not disclosed |
DisclosureSEC source: 0001453687-23-000088 · wk-form4_1700087164.xml · derivative · entry 5 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires 2028-11-30 F5 · price: This option, which provided for vesting as to 25% of the shares on December 1, 2019 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. F5 · derivative.exercise_date: This option, which provided for vesting as to 25% of the shares on December 1, 2019 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:26 UTC |
Brunn CarstenDirector · President and CEO
|
Disposition to issuerCommon Stock | 282,800 | $2.06 | $582,568.00 |
DisclosureSEC source: 0001453687-23-000088 · wk-form4_1700087164.xml · nonDerivative · entry 4 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,956 F4 · shares: This unvested restricted stock, which was granted on January 2, 2023, was canceled in the Merger, in exchange for $582,568, representing $2.06 per share, the Cash-out Amount as applied in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:26 UTC |
Brunn CarstenDirector · President and CEO
|
Disposition to issuerCommon Stock | 169,725 | $2.06 | $349,633.50 |
DisclosureSEC source: 0001453687-23-000088 · wk-form4_1700087164.xml · nonDerivative · entry 3 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 544,756 F3 · shares: This unvested restricted stock, which was granted on January 3, 2022, was canceled in the Merger, in exchange for $349,633.50, representing $2.06 per share, the Cash-out Amount as applied in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:26 UTC |
Brunn CarstenDirector · President and CEO
|
Disposition to issuerCommon Stock | 13,600 | $2.06 | $28,016.00 |
DisclosureSEC source: 0001453687-23-000088 · wk-form4_1700087164.xml · nonDerivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 714,481 F2 · shares: This unvested restricted stock, which was granted on September 24, 2021, was canceled in the Merger, in exchange for $28,016, representing $2.06 per share, the Cash-out Amount as applied in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:26 UTC |
Brunn CarstenDirector · President and CEO
|
Disposition to issuerCommon Stock | 55,000 | $2.06 | $113,300.00 |
DisclosureSEC source: 0001453687-23-000088 · wk-form4_1700087164.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 728,081 F1 · shares: This unvested restricted stock, which was granted on January 4, 2021, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc., in exchange for $113,300, representing $2.06 per share, the Cash-out Amount as applied in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:18 UTC |
DeSilva Nishan MDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 75,000 | $0.93 Strike: $1.13 | $69,750.00 |
DisclosureSEC source: 0001453687-23-000086 · wk-form4_1700086723.xml · derivative · entry 3 DeSilva Nishan M · CIK 0001492386 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2033-01-01 F3 · derivative.exercise_date: This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $69,750, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:18 UTC |
DeSilva Nishan MDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $3.31 | Not disclosed |
DisclosureSEC source: 0001453687-23-000086 · wk-form4_1700086723.xml · derivative · entry 2 DeSilva Nishan M · CIK 0001492386 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2032-01-02 F2 · price: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger. F2 · derivative.exercise_date: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:18 UTC |
DeSilva Nishan MDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 80,000 | Not disclosed Strike: $4.57 | Not disclosed |
DisclosureSEC source: 0001453687-23-000086 · wk-form4_1700086723.xml · derivative · entry 1 DeSilva Nishan M · CIK 0001492386 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2031-06-22 F1 · price: This option, which provided for vesting in thirty-six (36) substantially equal monthly installments over three years following the date of grant on June 23, 2021, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc. F1 · derivative.exercise_date: This option, which provided for vesting in thirty-six (36) substantially equal monthly installments over three years following the date of grant on June 23, 2021, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:26 UTC |
Davis BlaineChief Financial Officer
|
Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 1,250,000 | $0.79 Strike: $1.27 | $987,500.00 |
DisclosureSEC source: 0001453687-23-000089 · wk-form4_1700087199.xml · derivative · entry 1 Davis Blaine · CIK 0001802188 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250,000 shares Expires 2032-11-27 F1 · derivative.exercise_date: This option, which provided for vesting as to 25% on November 28, 2023 with the remainder of the underlying shares vesting in 36 equal monthly installments thereafter, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc., in exchange for a cash payment of $987,500, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:17 UTC |
Sallin AymericDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 75,000 | $0.93 Strike: $1.13 | $69,750.00 |
DisclosureSEC source: 0001453687-23-000084 · wk-form4_1700086654.xml · derivative · entry 7 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2033-01-01 F7 · derivative.exercise_date: This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $69,750, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:17 UTC |
Sallin AymericDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $3.31 | Not disclosed |
DisclosureSEC source: 0001453687-23-000084 · wk-form4_1700086654.xml · derivative · entry 6 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2032-01-02 F6 · price: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger. F6 · derivative.exercise_date: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:17 UTC |
Sallin AymericDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $4.01 | Not disclosed |
DisclosureSEC source: 0001453687-23-000084 · wk-form4_1700086654.xml · derivative · entry 5 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2031-03-29 F5 · price: This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger. F5 · derivative.exercise_date: This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:17 UTC |
Sallin AymericDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0001453687-23-000084 · wk-form4_1700086654.xml · derivative · entry 4 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2030-06-18 F4 · price: This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger. F4 · derivative.exercise_date: This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:17 UTC |
Sallin AymericDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $2.10 | Not disclosed |
DisclosureSEC source: 0001453687-23-000084 · wk-form4_1700086654.xml · derivative · entry 3 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2029-06-13 F3 · price: This option, which provided for vesting in full on June 14, 2020, was canceled in the Merger. F3 · derivative.exercise_date: This option, which provided for vesting in full on June 14, 2020, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:17 UTC |
Sallin AymericDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $12.75 | Not disclosed |
DisclosureSEC source: 0001453687-23-000084 · wk-form4_1700086654.xml · derivative · entry 2 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-06-14 F2 · price: This option, which provided for vesting in full on June 13, 2019, was canceled in the Merger. F2 · derivative.exercise_date: This option, which provided for vesting in full on June 13, 2019, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:17 UTC |
Sallin AymericDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 6,410 | Not disclosed Strike: $17.47 | Not disclosed |
DisclosureSEC source: 0001453687-23-000084 · wk-form4_1700086654.xml · derivative · entry 1 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,410 shares Expires 2027-06-15 F1 · price: This option, which provided for vesting in full on June 14, 2018, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc. F1 · derivative.exercise_date: This option, which provided for vesting in full on June 14, 2018, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:16 UTC |
Myers Scott DunsethDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 87,500 | $0.93 Strike: $1.13 | $81,375.00 |
DisclosureSEC source: 0001453687-23-000083 · wk-form4_1700086561.xml · derivative · entry 5 Myers Scott Dunseth · CIK 0001356256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 87,500 shares Expires 2033-01-01 F5 · derivative.exercise_date: This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $81,375, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:16 UTC |
Myers Scott DunsethDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $3.31 | Not disclosed |
DisclosureSEC source: 0001453687-23-000083 · wk-form4_1700086561.xml · derivative · entry 4 Myers Scott Dunseth · CIK 0001356256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2032-01-02 F4 · price: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger. F4 · derivative.exercise_date: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:16 UTC |
Myers Scott DunsethDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $4.01 | Not disclosed |
DisclosureSEC source: 0001453687-23-000083 · wk-form4_1700086561.xml · derivative · entry 3 Myers Scott Dunseth · CIK 0001356256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2031-03-29 F3 · price: This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger. F3 · derivative.exercise_date: This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:16 UTC |
Myers Scott DunsethDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0001453687-23-000083 · wk-form4_1700086561.xml · derivative · entry 2 Myers Scott Dunseth · CIK 0001356256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2030-06-18 F2 · price: This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger. F2 · derivative.exercise_date: This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:16 UTC |
Myers Scott DunsethDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $2.10 | Not disclosed |
DisclosureSEC source: 0001453687-23-000083 · wk-form4_1700086561.xml · derivative · entry 1 Myers Scott Dunseth · CIK 0001356256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2029-06-13 F1 · price: This option, which provided for vesting in thirty-six (36) substantially equal monthly installments over three years following the date of grant on June 14, 2019, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc. F1 · derivative.exercise_date: This option, which provided for vesting in thirty-six (36) substantially equal monthly installments over three years following the date of grant on June 14, 2019, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:15 UTC |
BARABE TIMOTHY CDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 87,500 | $0.93 Strike: $1.13 | $81,375.00 |
DisclosureSEC source: 0001453687-23-000082 · wk-form4_1700086521.xml · derivative · entry 7 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 87,500 shares Expires 2033-01-01 F7 · derivative.exercise_date: This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $81,375, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:15 UTC |
BARABE TIMOTHY CDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $3.31 | Not disclosed |
DisclosureSEC source: 0001453687-23-000082 · wk-form4_1700086521.xml · derivative · entry 6 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2032-01-02 F6 · price: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger. F6 · derivative.exercise_date: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:15 UTC |
BARABE TIMOTHY CDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $4.01 | Not disclosed |
DisclosureSEC source: 0001453687-23-000082 · wk-form4_1700086521.xml · derivative · entry 5 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2031-03-29 F5 · price: This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger. F5 · derivative.exercise_date: This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:15 UTC |
BARABE TIMOTHY CDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0001453687-23-000082 · wk-form4_1700086521.xml · derivative · entry 4 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2030-06-18 F4 · price: This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger. F4 · derivative.exercise_date: This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:15 UTC |
BARABE TIMOTHY CDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $12.75 | Not disclosed |
DisclosureSEC source: 0001453687-23-000082 · wk-form4_1700086521.xml · derivative · entry 3 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-06-14 F3 · price: This option, which provided for vesting in full on June 13, 2019, was canceled in the Merger. F3 · derivative.exercise_date: This option, which provided for vesting in full on June 13, 2019, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:15 UTC |
BARABE TIMOTHY CDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 6,410 | Not disclosed Strike: $17.47 | Not disclosed |
DisclosureSEC source: 0001453687-23-000082 · wk-form4_1700086521.xml · derivative · entry 2 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,410 shares Expires 2027-06-15 F2 · price: This option, which provided for vesting in full on June 14, 2018, was canceled in the Merger. F2 · derivative.exercise_date: This option, which provided for vesting in full on June 14, 2018, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:15 UTC |
BARABE TIMOTHY CDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 10,328 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0001453687-23-000082 · wk-form4_1700086521.xml · derivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,328 shares Expires 2026-07-28 F1 · price: This option, which provided for vesting in thirty-six (36) substantially equal monthly installments over three years following the date of grant on July 29, 2016, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc. F1 · derivative.exercise_date: This option, which provided for vesting in thirty-six (36) substantially equal monthly installments over three years following the date of grant on July 29, 2016, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:42 UTC |
Kurtoglu MetinChief Operations Officer
|
GrantStock Option (Right to Buy) · Derivative | 427.645 | Not disclosed Strike: $107.59 | Not disclosed |
DisclosureSEC source: 0001062993-23-020924 · form4.xml · derivative · entry 3 Kurtoglu Metin · CIK 0002000284 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 427.645 Underlying: Series A Non-Voting Convertible Preferred Stock · 427.645 shares Expires 2032-02-29 F3 · price: On November 13, 2023, the issuer acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Cartesian common stock held by the reporting person were converted into options to purchase shares of Series A Preferred Stock in connection with the acquisition. F4 · derivative.exercise_date: Option is currently exercisable for 106.911 shares of Series A Non-Voting Convertible Preferred Stock of the issuer ("Series A Preferred Stock") and becomes exercisable for the remaining shares in three equal tranches on March 1, 2024, 2025 and 2026. F2 · derivative.underlying: Following the approval by the stockholders of the issuer of the conversion of the Series A Preferred Stock into shares of common stock of the issuer ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:42 UTC |
Kurtoglu MetinChief Operations Officer
|
GrantStock Option (Right to Buy) · Derivative | 427.645 | Not disclosed Strike: $107.59 | Not disclosed |
DisclosureSEC source: 0001062993-23-020924 · form4.xml · derivative · entry 2 Kurtoglu Metin · CIK 0002000284 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 427.645 Underlying: Series A Non-Voting Convertible Preferred Stock · 427.645 shares Expires 2031-04-25 F3 · price: On November 13, 2023, the issuer acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Cartesian common stock held by the reporting person were converted into options to purchase shares of Series A Preferred Stock in connection with the acquisition. F1 · derivative.exercise_date: Option is fully exercisable. F2 · derivative.underlying: Following the approval by the stockholders of the issuer of the conversion of the Series A Preferred Stock into shares of common stock of the issuer ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:42 UTC |
Kurtoglu MetinChief Operations Officer
|
GrantStock Option (Right to Buy) · Derivative | 6,414.682 | Not disclosed Strike: $46.77 | Not disclosed |
DisclosureSEC source: 0001062993-23-020924 · form4.xml · derivative · entry 1 Kurtoglu Metin · CIK 0002000284 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,414.682 Underlying: Series A Non-Voting Convertible Preferred Stock · 6,414.682 shares Expires 2026-11-06 F3 · price: On November 13, 2023, the issuer acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Cartesian common stock held by the reporting person were converted into options to purchase shares of Series A Preferred Stock in connection with the acquisition. F1 · derivative.exercise_date: Option is fully exercisable. F2 · derivative.underlying: Following the approval by the stockholders of the issuer of the conversion of the Series A Preferred Stock into shares of common stock of the issuer ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:42 UTC |
Jewell Christopher MChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 4,276.454 | Not disclosed Strike: $107.59 | Not disclosed |
DisclosureSEC source: 0001062993-23-020923 · form4.xml · derivative · entry 1 Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,276.454 Underlying: Series A Non-Voting Convertible Preferred Stock · 4,276.454 shares Expires 2033-01-15 F3 · price: On November 13, 2023, the issuer acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Cartesian common stock held by the reporting person were converted into options to purchase shares of Series A Preferred Stock in connection with the acquisition. F1 · derivative.exercise_date: Option is currently exercisable for 2,539.177 shares of Series A Non-Voting Convertible Preferred Stock of the issuer ("Series A Preferred Stock") and becomes exercisable for an additional 89.093 shares each month until it is fully exercisable. F2 · derivative.underlying: Following the approval by the stockholders of the issuer of the conversion of the Series A Preferred Stock into shares of common stock of the issuer ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:41 UTC |
Singer MichaelDirector · 10% owner
|
OtherSeries A Non-Voting Convertible Preferred Stock · Derivative | 436.066 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-020922 · form4.xml · derivative · entry 14 Singer Michael · CIK 0002000122 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · by spouse Disclosed balance after: 436.066 Underlying: Common Stock · 436,066 shares Expires not disclosed F8 · derivative.exercise_price: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F1 · price: On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. F8 · derivative.exercise_date: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F8 · derivative.expiration_date: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F7 · ownership.nature: Shares are held by the reporting person's spouse. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:41 UTC |
Singer MichaelDirector · 10% owner
|
OtherSeries A Non-Voting Convertible Preferred Stock · Derivative | 2,837.052 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-020922 · form4.xml · derivative · entry 13 Singer Michael · CIK 0002000122 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · as custodian Disclosed balance after: 2,837.052 Underlying: Common Stock · 2,837,052 shares Expires not disclosed F8 · derivative.exercise_price: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F1 · price: On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. F8 · derivative.exercise_date: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F8 · derivative.expiration_date: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F6 · ownership.nature: The shares are held for SS, the child of the reporting person, through a custodial account established pursuant to the UTMA for which the reporting person serves as custodian. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:41 UTC |
Singer MichaelDirector · 10% owner
|
OtherSeries A Non-Voting Convertible Preferred Stock · Derivative | 2,837.052 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-020922 · form4.xml · derivative · entry 12 Singer Michael · CIK 0002000122 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · as custodian Disclosed balance after: 2,837.052 Underlying: Common Stock · 2,837,052 shares Expires not disclosed F8 · derivative.exercise_price: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F1 · price: On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. F8 · derivative.exercise_date: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F8 · derivative.expiration_date: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F5 · ownership.nature: The shares are held for LS, the child of the reporting person, through a custodial account established pursuant to the Uniform Transfer to Minors Act ("UTMA") for which the reporting person serves as custodian. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:41 UTC |
Singer MichaelDirector · 10% owner
|
OtherSeries A Non-Voting Convertible Preferred Stock · Derivative | 210.152 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-020922 · form4.xml · derivative · entry 11 Singer Michael · CIK 0002000122 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · by trust Disclosed balance after: 210.152 Underlying: Common Stock · 210,152 shares Expires not disclosed F8 · derivative.exercise_price: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F1 · price: On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. F8 · derivative.exercise_date: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F8 · derivative.expiration_date: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F4 · ownership.nature: Shares are held in a trust for which the reporting person is a beneficiary. The reporting person's spouse is a trustee of the trust. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:41 UTC |
Singer MichaelDirector · 10% owner
|
OtherSeries A Non-Voting Convertible Preferred Stock · Derivative | 1,672.389 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-020922 · form4.xml · derivative · entry 10 Singer Michael · CIK 0002000122 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · by trust Disclosed balance after: 1,672.389 Underlying: Common Stock · 1,672,389 shares Expires not disclosed F8 · derivative.exercise_price: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F1 · price: On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. F8 · derivative.exercise_date: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F8 · derivative.expiration_date: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3 · ownership.nature: Shares are held in a trust for which the reporting person is a beneficiary. The reporting person is a trustee of the trust. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:41 UTC |
Singer MichaelDirector · 10% owner
|
OtherSeries A Non-Voting Convertible Preferred Stock · Derivative | 11,316.263 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-020922 · form4.xml · derivative · entry 9 Singer Michael · CIK 0002000122 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · by trust Disclosed balance after: 11,316.263 Underlying: Common Stock · 11,316,263 shares Expires not disclosed F8 · derivative.exercise_price: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F1 · price: On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. F8 · derivative.exercise_date: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F8 · derivative.expiration_date: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F2 · ownership.nature: Shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the trust. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:41 UTC |
Singer MichaelDirector · 10% owner
|
GrantSeries A Non-Voting Convertible Preferred Stock · Derivative | 6,304.559 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-020922 · form4.xml · derivative · entry 8 Singer Michael · CIK 0002000122 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,304.559 Underlying: Common Stock · 6,304,559 shares Expires not disclosed F8 · derivative.exercise_price: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F1 · price: On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. F8 · derivative.exercise_date: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F8 · derivative.expiration_date: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:41 UTC |
Singer MichaelDirector · 10% owner
|
OtherCommon Stock | 7,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-020922 · form4.xml · nonDerivative · entry 7 Singer Michael · CIK 0002000122 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · by spouse Disclosed balance after: 7,616 F1 · price: On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. F7 · ownership.nature: Shares are held by the reporting person's spouse. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:41 UTC |
Singer MichaelDirector · 10% owner
|
OtherCommon Stock | 49,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-020922 · form4.xml · nonDerivative · entry 6 Singer Michael · CIK 0002000122 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · as custodian Disclosed balance after: 49,555 F1 · price: On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. F6 · ownership.nature: The shares are held for SS, the child of the reporting person, through a custodial account established pursuant to the UTMA for which the reporting person serves as custodian. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:41 UTC |
Singer MichaelDirector · 10% owner
|
OtherCommon Stock | 49,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-020922 · form4.xml · nonDerivative · entry 5 Singer Michael · CIK 0002000122 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · as custodian Disclosed balance after: 49,555 F1 · price: On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. F5 · ownership.nature: The shares are held for LS, the child of the reporting person, through a custodial account established pursuant to the Uniform Transfer to Minors Act ("UTMA") for which the reporting person serves as custodian. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:41 UTC |
Singer MichaelDirector · 10% owner
|
OtherCommon Stock | 3,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-020922 · form4.xml · nonDerivative · entry 4 Singer Michael · CIK 0002000122 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · by trust Disclosed balance after: 3,670 F1 · price: On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. F4 · ownership.nature: Shares are held in a trust for which the reporting person is a beneficiary. The reporting person's spouse is a trustee of the trust. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:41 UTC |
Singer MichaelDirector · 10% owner
|
OtherCommon Stock | 29,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-020922 · form4.xml · nonDerivative · entry 3 Singer Michael · CIK 0002000122 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · by trust Disclosed balance after: 29,212 F1 · price: On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. F3 · ownership.nature: Shares are held in a trust for which the reporting person is a beneficiary. The reporting person is a trustee of the trust. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:41 UTC |
Singer MichaelDirector · 10% owner
|
OtherCommon Stock | 197,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-020922 · form4.xml · nonDerivative · entry 2 Singer Michael · CIK 0002000122 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · by trust Disclosed balance after: 197,663 F1 · price: On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. F2 · ownership.nature: Shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the trust. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:41 UTC |
Singer MichaelDirector · 10% owner
|
GrantCommon Stock | 110,123 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-020922 · form4.xml · nonDerivative · entry 1 Singer Michael · CIK 0002000122 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,123 F1 · price: On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:41 UTC |
Kalayoglu MuratDirector · 10% owner
|
PurchaseSeries A Non-Voting Convertible Preferred Stock · Derivative | 619.627 | $249,999.98 | $154,906,737.61 |
DisclosureSEC source: 0001062993-23-020921 · form4.xml · derivative · entry 5 Kalayoglu Murat · CIK 0002000002 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · by trust Disclosed balance after: 619.627 Underlying: Common Stock · 619,627 shares Expires not disclosed F3 · derivative.exercise_price: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F4 · price: On November 13, 2023, the Trust entered into a Securities Purchase Agreement with the Company and other investors, pursuant to which the Trust agreed to acquire 619.627 shares of Series A Preferred Stock. F3 · derivative.exercise_date: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3 · derivative.expiration_date: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F2 · ownership.nature: Shares are held in a trust (the "Trust") for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the trust. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:41 UTC |
Kalayoglu MuratDirector · 10% owner
|
OtherSeries A Non-Voting Convertible Preferred Stock · Derivative | 189,136.767 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-020921 · form4.xml · derivative · entry 4 Kalayoglu Murat · CIK 0002000002 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · by trust Disclosed balance after: 189,136.767 Underlying: Common Stock · 189,136,767 shares Expires not disclosed F3 · derivative.exercise_price: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F1 · price: On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. F3 · derivative.exercise_date: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3 · derivative.expiration_date: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F2 · ownership.nature: Shares are held in a trust (the "Trust") for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the trust. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:41 UTC |
Kalayoglu MuratDirector · 10% owner
|
GrantSeries A Non-Voting Convertible Preferred Stock · Derivative | 14,755.609 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-020921 · form4.xml · derivative · entry 3 Kalayoglu Murat · CIK 0002000002 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,755.609 Underlying: Common Stock · 14,755,609 shares Expires not disclosed F3 · derivative.exercise_price: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F1 · price: On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. F3 · derivative.exercise_date: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3 · derivative.expiration_date: Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:41 UTC |
Kalayoglu MuratDirector · 10% owner
|
OtherCommon Stock | 3,303,699 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-020921 · form4.xml · nonDerivative · entry 2 Kalayoglu Murat · CIK 0002000002 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · by trust Disclosed balance after: 3,303,699 F1 · price: On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. F2 · ownership.nature: Shares are held in a trust (the "Trust") for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.